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Table 1. Characteristics of Patients with New Allergic Symptoms after Cord Blood Transplantation
Variable lists Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (gender) 54 (F) 41 (F) 39 (F) 3 (F) 43 (F)
Disease MDS CML/FCCL NK tcell lymphoma AML MDS/MPD
Pre-CBTallergy Codfish, celery, ginger None None None None
Conditioning regimen Flu/cy/tbi Flu/cy/tbi Flu/cy/tbi Cy/tbi/atg Flu/cy/tbi
CB cell dose 3.57 x 107 2.15 x 107 female 3.5x 107 3.86 x 107 5.02 x 107
GVHD prophylaxis FK and MMF FK and MMF FK and MMF FK and MMF FK and MMF
Acute GVHD + skin, + gut grade 2 + gut grade 2 + skin grade 3 None + gut grade 2
Chronic GVHD None + skin, gut , oral +gut and vaginal None None
Chimerism at the time
of new allergy
100% 100% 100% 100% 100%
New allergy documented
(days post- CBT)
+290 +250 +298 +809 +380
Impact on pre-CBT allergy Negative for previous allergies Na Na Na Na
Presenting sign and
symptoms
Vomiting with ingestion
of peanuts
Severe vomiting Throat closing swelling Painful itching blisters to
lips and mouth
Nausea/vomiting/diarrhea
Skin testing results + mites, cat, grass,
weed, tree, egg
white and yolk
+ grass, weeds, tress,
almond, walnut, brazil
nut, cashew, coconut
+ trees, grass, weeds, ragweed,
dust mites, dog, cat, peanut,
walnut, cashew, pecan, milk,
and egg
RAST 0.16kU/L (low) 5.88 kU/L (high)- almond;
and peanut 2.39 kU/L
(high)
Current IST None None None None None
Duration of follow-up (mo) 37 mo 39 mo 43 mo 46 mo 15mo
Current status Alive Alive Alive Alive Alive
CBT, cord blood transplantation; GVHD; Graft versus host disease.
*Result at the time of allergy evaluation; IST, immunosuppressive therapy; ALC, absolute lymphocyte count; mo, months; RAST, radioallergosorbent test.
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Introduction: Long term survivors of SCT have an increased risk of
cardiovascular disease which has not been well characterized.
Chronic GVHD (cGVHD) has been suspected to contribute to
this increased risk.
Methods: We evaluated the cardiovascular risk profiles in 109 sur-
vivors (62 males and 47 females) of SCT performed between 1993
and 2006. Median ages at transplant, 5 and 10 year post-SCT fol-
low-upwere 34, 40 and 46 years, respectively. Transplant indications
were CML (56), acute leukemia (29), MDS (13), and others (9).
Ninety-nine patients received $12 Gy TBI-based conditioning
and 10 patients received non-myeloablative conditioning followed
by marrow (15) or T cell depleted peripheral blood stem cell graft
(94). All females received hormone replacement therapy post-SCT.
Results:At the time of analysis, of 12 deaths, onewas due to a cardio-
vascular cause (stroke). Three survivors had non-fatal cardiovascular
events. There were significant increases in the prevalence of hyper-
tension (p# 0.001), diabetes (p5 0.018), elevatedC-reactive protein
(CRP) (p\0.001) and BodyMass Index (BMI) (p5 0.044) at follow-
up compared to baseline (Table). Survivors had higher rates of dys-
lipidemia meeting ATP III thresholds for drug therapy at 5 years
post-transplant (23%) compared to the general population (15%,
MESA study) (p\0.001). On calculating the Framingham general
cardiovascular risk score, the 10-year risk of developing a cardiovas-
cular event in male survivors at 5 years post-SCT nearly doubled
compared to normal (median 10.4% vs. 5.4%). The median calcu-
lated heart/vascular age was 8 years greater than the chronological
age for males. Females showed no increase in the cardiovascular
risk score. All risk factors stabilized between 5 and 10 years post-
SCT. cGVHD was not significantly associated with cardiovascular
risk factors at any time-point.
Conclusions: 1. Therapy requiring dyslipidemia in SCT survivors
occurs earlier and with a significantly greater frequency than in the
general population.2. At 5 years post transplant, male survivors have a doubling in the
10-year risk of developing a cardiovascular event and an 8-year in-
crease in heart/vascular age.
3. Although elevations in CRP suggest a persistent chronic inflam-
matory state, cGVHD does not impact cardiovascular risk.
Table.
Percentage increase in cardiovascular risk
factors from pre-transplant baseline at follow-up 5yrs (%) 10yrs (%)Diabetes 810 1005
Hypertension 292 563
Elevated BMI 14 58
CRP (as a continuous variable) 441 721223
PEDIATRIC REDUCED INTENSITY HEMATOPOIETIC PROGENITOR CELL
TRANSPLANTATION (HPCT) MAY CONFER LOWER RISK OF SECOND
MALIGNANT NEOPLASMS (SMNS)
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The occurrence of SMNs after HPCT is a potentially serious
problem for the pediatric population. Our initial intent was to com-
pare the incidence of SMNs in HPCT between traditional myeloa-
blative conditioning (TMC) and reduced intensity conditioning
(RIC) regimens, however, SMNs were only seen in the TMC group.
Conditioning regimen backbones were consistent within groups
with all allogeneic TMC SMNs having received total body irradia-
tion (TBI) 12 Gy, and RIC group with Fludarabine/Busulfan with-
out any radiation. Therefore, we compared the time at risk to
develop SMNs in the RIC group vs time to development in the
TMC group. Among pediatric patients who underwent HPCT in
our institution since 1992 and survived$ 3 years (n5 478; 166 allo-
geneic), 23 (5%) developed SMNs. Medical record review and
